Pharmacogenomics of HIV Therapy

HIV治疗的药物基因组学

• 批准号: 10596624
• 负责人: David W Haas
• 金额: $ 81.67万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-08 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10596624
• 关键词: AIDS clinical trial group; Acceleration; Affect; Anti-Retroviral Agents; Antiviral Agents; Biology; Cells; Chronic; Clinical; Clinical Trials; Collaborations; Complement; Complex Genetic Trait; Computerized Medical Record; Data; Data Analyses; Data Set; Databases; Drug Interactions; Drug Kinetics; Drug toxicity; Epidemiology; Exogenous Factors; FDA approved; Gene Expression; Gene Expression Profile; Generations; Genes; Genetic; Genetic Polymorphism; Genetic Transcription; Genome; Genomic approach; Genotype; Goals; HIV; HIV therapy; HIV-1; Heritability; Human Genetics; Human Genome; Immune; Individual; Infection; Inflammation; Injectable; Intervention; Intervention Trial; Laboratories; Messenger RNA; Metabolism; Methodology; Organ; Pathology; Pathway interactions; Patients; Persons; Pharmaceutical Preparations; Pharmacogenomics; Phenotype; Predisposition; Randomized; Recovery; Research; Research Personnel; Risk; Single Nucleotide Polymorphism; Specimen; System; Tablets; Technology; Therapeutic Intervention; Tissue-Specific Gene Expression; Tissues; Toxic effect; Transcript; Translating; Treatment-related toxicity; United States; Variant; Virus Replication; Visualization; Work; absorption; antiretroviral therapy; clinical care; clinical effect; clinically relevant; cohort; endophenotype; genetic association; genetic variant; genome wide association study; genome-wide; genomic data; immune activation; improved; inter-individual variation; interest; non-genetic; novel; novel therapeutics; phenome; polygenic risk score; prevent; prospective; response; trait; transcriptome; treatment response; whole genome

PROJECT SUMMARY Approximately 1.2 million individuals in the United States and 38 million worldwide are living with HIV. Priorities for HIV research include cure, mitigating associated inflammation and immune activation, novel therapeutics, and optimizing current management. In addition, there remains detrimental interindividual variability in HIV treatment responses regarding toxicities and immune recovery. Efforts to decipher relationships between the human genome and responses to therapeutic interventions in people living with HIV will help drive continued progress in the field, and involve complementary methodologies. The well-established value of the genome- wide association study (GWAS) is expanded by considering the polygenic risk score (PRS), which considers numerous polymorphisms that, in combination, affect risk for a phenotype, and by the integrated risk score (IRS), which combines PRS with non-genetic exposures. It is further expanded by the transcriptome-wide association study (TWAS), which relies on heritable gene expression in over 40 tissues throughout the body, inferred from genome-wide genotype data, and by the phenome-wide association study (PheWAS), which simultaneously interrogates genotype-phenotype associations across vast numbers of phenotypes. Complementing these variant-based and gene-based approaches are powerful wet-lab direct bulk and single- cell transcriptome analyses (TA) that decipher underlying biology by comparing patterns of gene expression between different experimental conditions or phenotypes. Building on progress to date, we will apply these complementary approaches to decipher genetic underpinnings of HIV-relevant clinical and endophenotypes, largely through analyses of available data and specimens from numerous different AIDS Clinical Trials Group trials and cohorts. We will consider interventions that target inflammation, the HIV reservoir, viral replication, and beyond. This work is facilitated by extensive groundwork laid by the proposing investigators to create and implement efficient, robust systems for variant-based, gene-based, and RNA expression-based genomic data generation and data analysis, as well as interpretation and visualization of results. Our ultimate goal is to improve the lives of people living with HIV through accelerated discovery based on state-of-the-art genomic approaches.

项目概要 美国大约有 120 万人，全世界大约有 3800 万人感染艾滋病毒。优先事项 HIV 研究包括治愈、减轻相关炎症和免疫激活、新疗法、 并优化现有管理。此外，艾滋病毒的个体间差异仍然存在。 有关毒性和免疫恢复的治疗反应。努力破译两者之间的关系 人类基因组和艾滋病毒感染者对治疗干预的反应将有助于推动持续 该领域的进展，并涉及补充方法。基因组的公认价值 广泛关联研究（GWAS）通过考虑多基因风险评分（PRS）进行了扩展，该评分考虑了 许多多态性结合起来影响表型的风险，并通过综合风险评分 (IRS)，它将 PRS 与非基因暴露结合起来。它通过转录组范围进一步扩展 关联研究 (TWAS)，依赖于全身 40 多个组织中的可遗传基因表达， 根据全基因组基因型数据和全表型关联研究 (PheWAS) 推断， 同时询问大量表型的基因型-表型关联。 对这些基于变体和基于基因的方法的补充是强大的湿实验室直接批量和单一 细胞转录组分析 (TA)，通过比较基因表达模式来解读潜在生物学 不同实验条件或表型之间的差异。基于迄今为止的进展，我们将应用这些 解读艾滋病毒相关临床和内表型的遗传基础的补充方法， 主要通过对来自众多不同艾滋病临床试验组的可用数据和样本进行分析 试验和队列。我们将考虑针对炎症、艾滋病毒储存库、病毒复制、 以及更远的地方。提议的调查人员为创建和建立广泛的基础奠定了广泛的基础，从而促进了这项工作 为基于变异、基于基因和基于 RNA 表达的基因组数据实施高效、稳健的系统 生成和数据分析，以及结果的解释和可视化。我们的最终目标是 通过基于最先进基因组的加速发现来改善艾滋病毒感染者的生活 接近。

项目成果

Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles.

HLA I 类和 II 类等位基因的共享肽结合与皮肤奈韦拉平超敏反应相关，并鉴定出新的风险等位基因。

• 发表时间: 2017
• 影响因子: 4.6
• 作者: Pavlos, Rebecca;McKinnon, Elizabeth J;Ostrov, David A;Peters, Bjoern;Buus, Soren;Koelle, David;Chopra, Abha;Schutte, Ryan;Rive, Craig;Redwood, Alec;Restrepo, Susana;Bracey, Austin;Kaever, Thomas;Myers, Paisley;Speers, Ellen;Malaker, Stacy A
• 通讯作者: Malaker, Stacy A

Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.

简要报告：艾滋病毒感染者的体重增加从基于依法韦仑的治疗方案转变为基于整合酶链转移抑制剂的治疗方案。

• 发表时间: 2017
• 作者: Norwood, Jamison;Turner, Megan;Bofill, Carmen;Rebeiro, Peter;Shepherd, Bryan;Bebawy, Sally;Hulgan, Todd;Raffanti, Stephen;Haas, David W;Sterling, Timothy R;Koethe, John R
• 通讯作者: Koethe, John R

Another Round of "Clue" to Uncover the Mystery of Complex Traits.

揭开复杂特征之谜的又一轮“线索”。

• 发表时间: 2018-01-25
• 影响因子: 3.5
• 作者: Verma, Shefali Setia;Ritchie, Marylyn D
• 通讯作者: Ritchie, Marylyn D

Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population.

非洲人群中多替拉韦神经精神不良事件的药代动力学和药物遗传学关联。

• 发表时间: 2022-10-28
• 作者: Griesel, Rulan;Sinxadi, Phumla;Kawuma, Aida;Joska, John;Sokhela, Simiso;Akpomiemie, Godspower;Venter, Francois;Denti, Paolo;Haas, David W;Maartens, Gary
• 通讯作者: Maartens, Gary

Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral dose.

单次口服剂量后依非韦伦药代动力学和药物遗传学的神经心理学相关性。

• 发表时间: 2013-04
• 影响因子: 3.4
• 作者: Johnson, Daniel H;Gebretsadik, Tebeb;Shintani, Ayumi;Mayo, Gail;Acosta, Edward P;Stein, C Michael;Haas, David W
• 通讯作者: Haas, David W